The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis (NCT05564936)
The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis: a Validation Study
🩺 Plain-English Summary (8th-Grade Level)
ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Denver — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- University of Colorado Denver — Aurora, Colorado
- University of Florida Health — Jacksonville, Florida
- HealthParterns Institute — Bloomington, Indiana
- Indiana University Health — Indianapolis, Indiana
- University of Kentucky — Lexington, Kentucky
- Neurological Associates of Long Island, P.C. — Lake Success, New York
- Duke University — Durham, North Carolina
- OHSU — Portland, Oregon
- Thomas Jefferson University — Philadelphia, Pennsylvania
- The University of Tennessee Medical Center — Knoxville, Tennessee
- Vanderbilt Health — Nashville, Tennessee
- Hôpital Raymond Poincaré — Garches,
- CHU Grenoble — Grenoble,
- Hôpital Salengro — Lille,
- CHRU Nancy — Nancy,
- CHU Nantes — Nantes,
- Pitié-Salpêtrière — Paris,
- CHU de Strasbourg - Hôpital de Hautepierre — Strasbourg,
- CHU Toulouse — Toulouse,
📞 Contact the Study Coordinator
Phone: +33147107752
Email: pascal.laforet@aphp.fr
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myasthenia Gravis
- Myasthenia Gravis Inebilizumab Trial — Orange, California
- Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis — Phoenix, Arizona
- Multi-Modal Monitoring of Disease Symptoms in Myasthenia Gravis — Boston, Massachusetts
- Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis — Saint Paul, Minnesota
- A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis — Phoenix, Arizona
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) — Colorado Springs, Colorado
Explore by condition: All Myasthenia Gravis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.